References of "VAN OVERMEIRE, Lionel"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPeritoneal equilibration test with conventional ‘low pH/high glucose degradation product’ or with biocompatible ‘normal pH/low glucose degradation product’ dialysates: does it matter?
VAN OVERMEIRE, Lionel ULg; Goffin, Eric; Krzesinski, Jean-Marie ULg et al

in Nephrology Dialysis Transplantation (2013)

Abstract Background. The evaluation of the peritoneal transport characteristics is mandatory in peritoneal dialysis (PD) patients. This is usually performed in routine clinical practice with a peritoneal ... [more ▼]

Abstract Background. The evaluation of the peritoneal transport characteristics is mandatory in peritoneal dialysis (PD) patients. This is usually performed in routine clinical practice with a peritoneal equilibration test (PET) using conventional dialysates, with low pH and high glucose degradation product (GDP) concentrations. An increasing proportion of patients are now treated with biocompatible dialysates, i.e. with physiological pH and lower GDP concentrations. This questions the appropriateness to perform a PET with conventional solutions in those patients. The aim of our study is to compare the results of the PET using biocompatible and conventional dialysates, respectively. Methods. Nineteen stable PD patients (13 males, 6 females; mean age: 67.95 ± 2.36 years, mean body surface area: 1.83 ± 0.04 m2, dialysis vintage: 2.95 ± 0.19 years) were included, among which 10 were usually treated with biocompatible and 9 with conventional solutions. Two PETs were performed, within a 2-week interval, in each patient. PET sequence (conventional solution first or biocompatible solution first) was randomized in order to avoid ‘time bias’. Small (urea, creatinine and glucose), middle (beta-2-microglobulin) and large molecules’ (albumin and alpha-2-macroglobulin) dialysate/plasma (D/P) concentration ratios and clearances were measured during each PET. Ultrafiltration (UF) and sodium filtration were also recorded. Results of both tests were compared by the Wilcoxon paired test. Results. No statistical difference was found between both dialysates for small molecule transport rates or for sodium filtration and UF. However, a few patients were not similarly classified for small-solute transport characteristics within the PET categories. Beta-2-microglobulin and albumin D/P ratios at different time points of the PET were significantly higher with the biocompatible, when compared with the conventional, solutions: 0.10 ± 0.03 versus 0.08 ± 0.02 (P < 0.01) and 0.008 ± 0.003 versus 0.007 ± 0.003 (P = 0.01), respectively. A similar difference was also observed for beta-2-microglobulin that was higher with biocompatible dialysates (1.04 ± 0.32 versus 0.93 ± 0.32 mL/min, respectively). Conclusion. Peritoneal transport of water and small solutes is independent of the type of dialysate which is used. This is not the case for the transport of beta-2-microglobulin and albumin that is higher under biocompatible dialysates. Vascular tonus modification could potentially explain such differences. The PET should therefore always be carried out with the same dialysate to make longitudinal comparisons possible. [less ▲]

Detailed reference viewed: 35 (5 ULg)
Full Text
Peer Reviewed
See detailNutritional disorders during acute renal failure and renal replacement therapy
WIESEN, Patricia ULg; VAN OVERMEIRE, Lionel ULg; DELANAYE, Pierre ULg et al

in JPEN Journal of Parenteral & Eternal Nutrition (2011), 35

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailLa glomérulonéphrite fibrillaire non amyloïde : une cause rare de syndrome néphrotique
GROSCH, Stéphanie ULg; VAN OVERMEIRE, Lionel ULg; Krzesinski, Jean-Marie ULg et al

in Néphrologie & Thérapeutique (2011), 7

La glomérulonéphrite fibrillaire non amyloïde est une pathologie glomérulaire à dépôts fibrillaires, non amyloïdes, composés principalement d'immunoglobulines G polyclonales. Il s'agit d'une ... [more ▼]

La glomérulonéphrite fibrillaire non amyloïde est une pathologie glomérulaire à dépôts fibrillaires, non amyloïdes, composés principalement d'immunoglobulines G polyclonales. Il s'agit d'une glomérulopathie idiopathique responsable de protéinurie sévère, souvent néphrotique et d'insuffisance rénale arrivant à un stade terminal dans 40% des cas à cinq ans. Elle peut prendre différents aspects anatomopathologiques déterminants en terme de pronostic rénal. La négativité des dépôts en coloration rouge Congo et l'épaisseur des fibrilles en microscopie électronique permettent le diagnostic différentiel avec les dépôts amyloïdes. Il n'y a pas de traitement efficace. Après transplantation rénale, la récidive est fréquente avec un pronostic rénal cependant moins péjoratif. [less ▲]

Detailed reference viewed: 72 (2 ULg)
Full Text
Peer Reviewed
See detailComparaison de l'évaluation des propriétés de transport tranpéritonéal au moyen d'un dialysat "conventionnel" par rapport à un nouveau dialysat dit "biocompatible"
Van Overmeire, Lionel ULg; Goffin, E.; Bovy, Philippe et al

in Néphrologie & Thérapeutique (2010, September 30), 6

Detailed reference viewed: 46 (2 ULg)
Full Text
Peer Reviewed
See detailNouveautés dans la prise en charge des anomalies du bilan phosphocalcique chez le patient dialysé
Delanaye, Pierre ULg; Van Overmeire, Lionel ULg; Dubois, Bernard ULg et al

in Revue Médicale de Liège (2007), 62(5-6, May-Jun), 360-5

Disorders of the phosphocalcic metabolism are frequent in dialysis patients. Such disorders are difficult to treat and have negative impact on bone health, but also on cardiovascular mortality ... [more ▼]

Disorders of the phosphocalcic metabolism are frequent in dialysis patients. Such disorders are difficult to treat and have negative impact on bone health, but also on cardiovascular mortality. Hyperphosphoremia is a strong predictor of cardiovascular mortality. New phosphate binders are now available in Belgium. A new molecule acting on the calcium receptor of the parathyroid glands is able to control secondary and tertiary hyperparathyroidism in dialysis patients. These new therapies, specific for dialysis patients, will be reviewed in this article. [less ▲]

Detailed reference viewed: 139 (27 ULg)
Full Text
Peer Reviewed
See detailNouveautés dans la prise en charge médicale des anomalies du bilan phosphocalcique chez le patient hémodialysé
Van Overmeire, Lionel ULg; Delanaye, Pierre ULg; Krzesinski, Jean-Marie ULg

in Revue Médicale Suisse (2005), 1(30), 1960-5

Bone metabolism is very frequently disturbed in end stage renal failure hemodialyzed, with secondary hyperparathyroidism development but also serious potential cardiovascular consequences. New treatments ... [more ▼]

Bone metabolism is very frequently disturbed in end stage renal failure hemodialyzed, with secondary hyperparathyroidism development but also serious potential cardiovascular consequences. New treatments will be available very soon in Europe such as new phosphate binders, vitamin D2 analogues or calcimimetics to fight against such medical diseases, with the hope of less risk for vascular complications. The real place of such new medical opportunities needs to be determined. Moreover, studies with morbidity and mortality end-points are waited before estimating the real importance of these new therapeutic tools. [less ▲]

Detailed reference viewed: 76 (1 ULg)
Full Text
See detailLe coenzyme Q10: biochimie, physiopathologie de sa carence et interet potentiel d'une augmentation de ses apports.
Malchair, P.; Van Overmeire, Lionel ULg; Boland, André ULg et al

in Revue Médicale de Liège (2005), 60(1), 45-51

After a brief reminding of the synthesis and function of coenzyme Q10, this article tries to summarise the current state of knowledge about the consequences of its deficiency and about the potential ... [more ▼]

After a brief reminding of the synthesis and function of coenzyme Q10, this article tries to summarise the current state of knowledge about the consequences of its deficiency and about the potential benefits of an increased intake of this coenzyme. We then describe the arguments in favour of such an increase in cardiac diseases and in Parkinson's disease. [less ▲]

Detailed reference viewed: 234 (39 ULg)
Full Text
Peer Reviewed
See detailElectrophysiological characterization of the SK channel blockers methyl-laudanosine and methyl-noscapine in cell lines and rat brain slices
Scuvée-Moreau, Jacqueline ULg; Boland, André ULg; Graulich, Amaury ULg et al

in British Journal of Pharmacology (2004), 143(6), 753-764

We have recently shown that the alkaloid methyl-laudanosine blocks SK channel-mediated afterhyperpolarizations (AHPs) in midbrain dopaminergic neurones. However, the relative potency of the compound on ... [more ▼]

We have recently shown that the alkaloid methyl-laudanosine blocks SK channel-mediated afterhyperpolarizations (AHPs) in midbrain dopaminergic neurones. However, the relative potency of the compound on the SK channel subtypes and its ability to block AHPs of other neurones were unknown. Using whole-cell patch-clamp experiments in transfected cell lines, we found that the compound blocks SK1, SK2 and SK3 currents with equal potency: its mean IC(50)s were 1.2, 0.8 and 1.8 microM, respectively. IK currents were unaffected. In rat brain slices, methyl-laudanosine blocked apamin-sensitive AHPs in serotonergic neurones of the dorsal raphe and noradrenergic neurones of the locus coeruleus with IC(50)s of 21 and 19 microM, as compared to 15 microM in dopaminergic neurones. However, at 100 microM, methyl-laudanosine elicited a constant hyperpolarization of serotonergic neurones of about 9 mV, which was inconsistently (i.e. not in a reproducible manner) antagonized by atropine and hence partly due to the activation of muscarinic receptors. While exploring the pharmacology of related compounds, we found that methyl-noscapine also blocked SK channels. In cell lines, methyl-noscapine blocked SK1, SK2 and SK3 currents with mean IC(50)s of 5.9, 5.6 and 3.9 microM, respectively. It also did not block IK currents. Methyl-noscapine was slightly less potent than methyl-laudanosine in blocking AHPs in brain slices, its IC(50)s being 42, 37 and 29 microM in dopaminergic, serotonergic and noradrenergic neurones, respectively. Interestingly, no significant non-SK effects were observed with methyl-noscapine in slices. At a concentration of 300 microM, methyl-noscapine elicited the same changes in excitability in the three neuronal types than did a supramaximal concentration of apamin (300 nM). Methyl-laudanosine and methyl-noscapine produced a rapidly reversible blockade of SK channels as compared with apamin. The difference between the IC(50)s of apamin (0.45 nM) and methyl-laudanosine (1.8 microM) in SK3 cells was essentially due to a major difference in their k(-1) (0.028 s(-1) for apamin and >or=20 s(-1) for methyl-laudanosine). These experiments demonstrate that both methyl-laudanosine and methyl-noscapine are medium potency, quickly dissociating, SK channel blockers with a similar potency on the three SK subtypes. Methyl-noscapine may be superior in terms of specificity for the SK channels. [less ▲]

Detailed reference viewed: 103 (31 ULg)